Australia and European Union mutual recognition virtually complete
This article was originally published in Clinica
Agreement on mutual recognition of conformity assessment between Australia and the EU "is virtually complete", according to the Australian Therapeutic Device Bulletin. The agreement will cover all devices subject to the EU Active Implantable Medical Device and Medical Device Directives and all devices covered by the Therapeutic Goods Act in Australia, apart from radioactive substances, some materials of animal origin, a number of devices containing pharmaceutical substances and products previously banned in any country.
You may also be interested in...
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.